http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Acerus Announces Resignation of CFO Effective November 20, 2022
-
Acerus Reports Second Quarter 2022 Financial Results
-
Acerus Announces Amendments to Loan Facility and Promissory Note Due to Former Serenity Shareholders
-
Acerus to Report Q2-2022 Financial Results and Host Investor Call
-
Acerus Announces Voting Results for the 2022 Annual Meeting
-
Acerus Announces Amendments to Loan Facility
-
Acerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity Securityholders
-
Acerus Reports First Quarter 2022 Financial Results
-
Acerus To Report Q1-2022 Financial Results And Host Investor Call
-
Acerus Announces Completion of Share Consolidation
-
Acerus Announces Share Consolidation
-
Acerus Announces Amendments to Loan Facility
-
Acerus Reports Fourth Quarter and Full Year 2021 Financial Results
-
Acerus To Report Q4 And Full Year 2021 Financial Results And Host Investor Call
-
Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva™
-
Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™
-
Acerus Announces Amendment to Loan Facilities
-
Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto Rico
-
Acerus Announces Amendments to Loan Facilities
-
Acerus Reports Fiscal Third Quarter Financial Results
-
Acerus to Report Q3-2021 Financial Results and Host Investor Call
-
Acerus Announces Participation in HC Wainwright Conference
-
Acerus Reports Acceptance of Part 36 Settlement Offer in Recipharm Litigation
-
Acerus Reports Fiscal 2021 Second Quarter Financial Results
-
Acerus to Report Q2-2021 Financial Results and Host Investor Call
-
Acerus Provides Update on Litigation with Recipharm
-
Acerus Announces New PBM Contract, Significantly Expanding NATESTO® Insurance Coverage in the United States
-
Acerus Announces Voting Results for the 2021 Annual Meeting
-
Acerus Reports First Quarter 2021 Financial Results
-
Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®
-
Acerus to Report Q1-2021 Financial Results and Host Investor Call
-
Acerus Announces Closing of US$15 Million Secured Loan Facility
-
Acerus Buys Back All Remaining U.S. Rights for NATESTO® From Aytu
-
Acerus Announces Expansion of NATESTO® Distribution Worldwide
-
Acerus Announces Amendment to Credit Agreement
-
Acerus Reports Fourth Quarter and Full Year 2020 Financial Results
-
Acerus to Report 2020 Financial Results and Host Investor Call
-
Acerus Announces Waiver of Q4 Financial Covenant in Credit Agreement
-
Acerus Announces Details of Previously Completed Rights Offering
-
Acerus Announces Completion of Over-Subscribed Rights Offering
-
Acerus Reports Fiscal Third Quarter Financial Results
-
Acerus to Report Third Quarter 2020 Financial Results and Host Investor Call
-
Acerus Announces Rights Offering and Standby Commitment
-
Acerus Announces Waiver of Third Quarter Financial Covenant in Credit Agreement
-
Acerus Announces Addition of US Commercial Leader
-
Acerus Reports Fiscal 2020 Second Quarter Financial Results
-
Acerus to Report Second Quarter 2020 Financial Results and Host Investor Conference Call
-
Acerus Announces Resumption of NATESTO® Shipments
-
Acerus Announces Addition of Chief Medical Officer
-
Acerus Announces Launch of NATESTO® Specialty Sales Team in the United States
